Securing Buy-In from Pharma Partnerships and Investors
Time: 2:30 pm
day: Conference Day 2
Details:
- How can we effectively present proof of concept, pharmacokinetic (PK), and toxicity data to persuade conservative investors to fund next-generation conjugate projects in Europe?
- Which specific metrics and evidence, such as efficacy data, market potential, or comparative advantages over existing therapies, are most persuasive for investors when considering funding for next-generation conjugates?
- In what ways can collaborative ventures and strategic partnerships between academia, industry, and investors be leveraged to mitigate funding challenges and foster investment in the development of next-generation conjugates within Europe?
